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Objective: To examine the proportion of isolated patellofemoral osteoarthritis (PFOA) compared to
tibiofemoral osteoarthritis (TFOA) in middle-aged participants with early osteoarthritis (OA) symptoms
of the knee; to describe the natural course of PFOA compared with that of TFOA and to identify whether
patients with PFOA have a different phenotype compared to patients with TFOA, or with combined PFOA
and TFOA (combined osteoarthritis (COA)).
Design: Participants with early OA symptoms of the knee were selected, completed questionnaires,
underwent physical examination, and had knee radiographs at baseline, and at 2 and 5 years follow-up.
Based on radiographs, participants were classified as having isolated TFOA, isolated PFOA, COA, or no
radiographic OA. Multivariate logistic regression was used to identify participant characteristics associ-
ated with a specific group of OA at 2 years follow-up.
Results: The cohort comprised 845 participants (mean age 55.9 years). At baseline, 116 had PFOA, none
had TFOA or COA. Of these 116 participants, 66.3% had developed COA at 5 years follow-up. At 2 years
follow-up, PFOA, TFOA and COA were present in 77 (10.8%), 39 (5.5%) and 83 (11.6%) participants,
respectively. Multivariate regression analyses at 2 years follow-up showed that participants with
radiographic PFOA or TFOA were not significantly different from each other with respect to signs and
symptoms.
Conclusions: These results suggest that OA is more likely to start in the patellofemoral joint and then
progress to COA in individuals with symptoms of early knee OA. No differences in TFOA and PFOA
phenotypes were determined with respect to signs and symptoms.
© 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The most common condition to affect the knee joint is osteo-
arthritis (OA)1,2. The knee joint consists of two compartments the
tibiofemoral (TF) and the patellofemoral (PF) compartment. OA in
the knee can occur solely in the TF joint [isolated tibiofemoral
osteoarthritis (TFOA)] or in the PF joint [isolated patellofemoral
osteoarthritis (PFOA)] or can be present in both joints [combined
TFOA and PFOA (combined osteoarthritis (COA))]. Most research onto: M. van Middelkoop,
ty Medical Centre, P.O. Box
(M. van Middelkoop).
ternational. Published by Elsevier LOA has focused on the TF joint, although the prevalence of isolated
PFOA might be higher than isolated TFOA3e6. Furthermore, radio-
graphic signs of PFOA are associated with symptoms such as pain
and disability7e10.
Although the main goal of treatment for OA is pain relief, not
every participant responds equally well to treatment11,12. One
possible reason for this difference is that the heterogeneous OA
population consists of persons with different phenotypes of
OA12e14. Identification of the distinct phenotypes in OA may help
classify which preventive measures are suitable for an individual14.
Therefore, it is suggested to target interventions to different OA
phenotypes15e18. However, Mills and Hunter stated: ‘due to the in-
clusion of homogenous study groups based on TFOA in clinical trials,td. All rights reserved.
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cohort studies that include participants with COA and isolated
TFOA and PFOA are needed to determine whether participants with
PFOA have a different phenotype compared to those with TFOA
or COA.
Additionally, evidence from a study including participants aged
50 years with knee complaints suggests that OA in the knee starts
in the PF joint and subsequently progresses to the TF joint20. This
was recently strengthened by Stefanik et al. (2016) who found that
knees with structural damage in one compartment of the knee do
not develop structural damage in another compartment. Moreover,
knees that developed mixed structural damage were more likely to
start with isolated to the PF joint21. Therefore, more insight is
required in the natural course of PFOA and how its natural course
differs from TFOA. The few studies describing the prevalence and
natural course of TFOA and PFOA included participants with severe
signs of OA on radiographs22 or studied a general population
including individuals without knee complaints9,23. Other studies
focussing on TFOA and PFOA included participants with a relatively
high age (mean age 68.4, 65.2 and 62.5 years, respectively)20,21,24,25.
Although two studies evaluated the prevalence of PFOA in a
younger population (aged 34e55 years), these participants had
chronic knee complaints26 or no baseline X-ray data of the PF joint
were available so that progression could not be evaluated27. Thus,
most research has focused on older participants with a longer
symptom duration of knee pain, or on the general population and
therefore little is known on the incidence and prevalence rates, as
well as the natural course of PFOA and TFOA, in relatively young
subjects with a recent onset of knee complaints.
Therefore, the aim of this study is to 1) determine the propor-
tion PFOA compared to TFOA in individuals with early knee OA
symptoms; 2) describe the natural course of PFOA at 2 and 5 years
follow-up compared with that of TFOA; and 3) identify whether
participants with PFOA have a different phenotype of signs and
symptoms compared to those with TFOA, and those with COA.
Methods
Study population
The present study used baseline data, and data from 2 to 5 years
follow-up of the Cohort Hip and Cohort Knee study (CHECK). A
detailed description of this cohort is published elsewhere28,29. In
brief, the cohort included 1002 participants recruited between
October 2002 and September 2005. Inclusion criteria were: par-
ticipants aged 45e65 years with hip and/or knee complaints (pain
or stiffness) who had never visited a general practitioner (GP) for
their complaints, or had visited a GP no longer than 6 months
previously.
Participants were excluded if they had a pathologic disorder
(based on medical history and physical examination) that also
could explain the symptoms (e.g., for the knee; other rheumatic
disease, ligament or meniscus injury, knee joint replacement, plica
syndrome, Baker's cyst); had a serious comorbidity that did not
allow physical evaluation/follow-up for up to 10 years; and did not
have adequate understanding of the Dutch language28.
For the current study only those participants that reported knee
pain or knee stiffness at baseline were included (n ¼ 845). Ethical
approval was obtained and participants provided informed consent
prior to commencement of the study28.
Questionnaires
Self-reported questionnaires were filled in yearly by all partici-
pants. At baseline and at follow-up the following domains wereassessed by questionnaires: 1) Socio-demographic characteristics:
age (in years), sex (male/female), body height (m) and weight (kg),
2) Knee symptoms: duration of complaints (only assessed at
baseline), side of knee pain, number of subjects with hip and knee
symptoms, and the Western Ontario and McMaster Universities
Index (WOMAC)30 for knee function (higher scores indicating
worse function). Moreover, information on pain when going up/
down upstairs and when walking on a flat surface was obtained by
means of a five-point Likert scale (‘none’, ‘slight’, ‘moderate’, ‘se-
vere’, ‘extreme’)30.
Physical examination
All participants underwent a standardised physical examination
at baseline, and at 2 and 5 years follow-up. For the present study,
we used data of the physical examination at baseline and data of
the 2-year follow-up of the index knee (i.e., the most affected
knee)31. Of the 845 participants with knee pain, 384 (44.5%) had
unilateral symptoms. For participants with bilateral symptoms the
index knee was based on the following decision tree as described
by Holla et al.31 1) highest Kellgren/Lawrence score, 2) lowest de-
gree of active knee flexion, 3) highest pain during knee flexion, and
4) crepitus during knee flexion. In participants for whomwe could
not define an index knee based on these signs, we randomly
assigned an index joint.
Range of joint motion was measured with a goniometer (in
degrees). To assess knee effusion the refill test was used (present or
absent), palpable warmth was determined by comparing both
knees with each other (present or absent), and bony enlargement,
joint line tenderness, crepitus (during squatting) and PF grinding
test were all scored for presence or absence by palpation.
Radiographs
At baseline and at 2 and 5 years follow-up, weight-bearing
posterioreanterior (PA), with 7e10; knee flexion; lateral weight-
bearing radiographs with 30 of knee flexion; and skyline view
with the knees in 30 flexion were made of both knees separately.
For the PA radiographs individual features of OA were scored ac-
cording to the atlas of Altman et al.32 The following features of OA
were scored: joint space narrowing (none, doubtful, mild or mod-
erate), femoral medial and lateral osteophytes, and tibial medial
and lateral osteophytes (none tomoderate). The original Kellgren&
Lawrence (K&L) criteria were used to score the severity of TFOA of
the involved knee on the PA radiographs33. On the lateral views
osteophytes (none to moderate) were scored and on the skyline
view osteophytes (none to moderate) and joint space narrowing
(none tomoderate) were scored according to Burnett et al.34. All the
above-mentioned features were scored by five observers inde-
pendently, according to a paired reading procedure (inter-reader
reliability: 0.62)35.
Definition of radiographic OA per compartment
The type of OAwas defined for the index knee of the individual.
Patients were classified having no OA, isolated PFOA, isolated
TFOA or combined OA. Patients classified having isolated PFOA
only had signs of OA in the PF joint, patients with isolated TFOA
only had signs of OA in the TF joint, and none in the PF joint. and
patients with COA had signs of OA in both the TF and the PF
joint (Table I). No radiographic OA was defined if none of the
definitions was fulfilled. Incident cases at 2 or 5 years follow-up
were defined as participants with radiographic signs of any type
of OA at follow-up who did not have signs of OA at baseline or at 2
years follow-up4,23.
Table I
Radiographic criteria for PFOA, TFOA and COA
Isolated PFOA Isolated TFOA Combined OA
K&L score <2 on PA radiographs and osteophytes
grade 2 on skyline
K&L score 2 on PA radiographs and osteophytes
grade <2 on both skyline and lateral radiographs
K&L score 2 on PA radiographs and skyline or
lateral osteophytes grade 2
OR OR OR
K&L score <2 on PA radiographs and osteophytes
grade 2 on lateral radiographs
K&L score 2 on PA radiographs and narrowing
grade <2 and osteophytes grade <1 for skyline
radiographs
K&L score 2 on PA radiographs and narrowing
grade 2 and osteophytes grade 1 for skyline
radiographs
OR
K&L <2 on PA radiographs and narrowing grade 2
and osteophytes grade 1 for skyline
radiographs
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To determine the proportion PFOA compared to TFOA in in-
dividuals with early knee OA symptoms, descriptive statistics
(mean, standard deviations [SD] and proportions) were applied.
Descriptive statistics were also applied to determine the natural
course of PFOA and TFOA at 2 and 5 years follow-up. Differences in
characteristics between study groups at baseline and at 2 years
follow-up were analysed using ANOVA tests and posthoc Bonfer-
roni tests were performed when P < 0.05.
To identify whether participants with PFOA had a different
phenotype of signs and symptoms compared to those with TFOA,
and those with COA multivariate binary logistic regression (based
on complete case analyses) (P < 0.01) was used. For the analyses
data at 2 years follow-up were used because none of the partici-
pants had TFOA or COA at baseline so that we were unable to test
for differences in phenotypes at baseline. The following variables
were included in the regression analyses: gender, age, body mass
index (BMI), pain whenwalking up/down stairs and whenwalking
on a flat surface [both dichotomised into no pain (‘none’ and
‘slight’) and painful (‘moderate’, ‘severe’ and ‘extreme’)], function
score (WOMAC), bony tenderness during palpation, joint line
tenderness, crepitus in the knee duration flexion, degrees of knee
flexion and extension, and the patellar grinding test. This selection
of characteristics was based on the literature and their practica-
bility in general practice20,25,36. Significance level was set at
P < 0.01, and a significant trend was defined as a P-value >0.01 and
<0.05. Analyses were based on complete case analyses (i.e., no
missing radiograph and physical examination). Analyses were
performed using the Statistical Package for the Social Sciences
version 21.0 (SPSS Inc., Chicago IL, USA).Results
Study population
At baseline, the total cohort comprised 845 participants (80%
females) who reported knee pain or stiffness. The mean age was
55.9 (5.18) years and mean BMI was 26.3 (4.15) kg/m2. Due to
missing data, the type of OA could not be determined for 139
(16.4%),129 (15.3%) and 150 (17.8%) participants at baseline and at 2
and 5 years follow-up, respectively.Incidence and prevalence of different types of OA
Of the 706 participants available at baseline, 116 (16.4%) had
isolated PFOA and none had TFOA or COA; 590 participants had no
radiographic defined OA at baseline. The presence of isolated PFOA
in those with knee pain at baseline was associated with higher age,
higher BMI, hip pain at baseline, crepitus, positive PF grinding test,palpable bony enlargement, lower knee flexion range of motion
(ROM) and a K&L score 1 (Table II).
At 2-year follow-up, isolated PFOA was found in 77 (10.8%)
participants. Posthoc analyses of ANOVA showed that participants
with PFOA had a significantly lower BMI, hadmore knee flexion and
less knee effusion compared to participants with COA at 2-year
follow-up (Table II). At the 5-year follow-up, 100 (14.4%) partici-
pants were diagnosed with isolated PFOA.
Natural course of PFOA and TFOA
Of the 116 participants with isolated PFOA at baseline, 63
(54.3%) had developed COA at the 2-year follow-up and 62 (53.4%)
had developed COA at the 5-year follow-up. The status of five
participants with PFOA at baseline was unknown due to missing
data at both 2 and 5 year follow-up. Seven of the 116 participants
had already progressed to COA at 2-years follow-up, but had
missing data at 5-years follow-up and three participants were
diagnosed with PFOA at baseline and 2-years follow-up, but had
missing data at 5-years follow-up (Fig. 1).
Of the 77 participants with PFOA at 2-year follow-up, 48 (62.3%)
already had PFOA at baseline, 27 were new incident cases and two
PFOA patients had missing data at baseline. Isolated TFOA was
present in 39 (5.5%) participants, none of them had signs of OA at
baseline. COA was present in 83 (11.6%) participants at 2 years
follow-up; 63 (75.9%) had PFOA at baseline,18 patients did not have
signs of OA at baseline and two patients had missing data at
baseline (Fig. 1).
At the 5-year follow-up, 100 participants were diagnosed with
isolated PFOA: .39 already had PFOA at baseline and 2-years follow-
up, 23 had PFOA at 2-years and 30 did not have signs of OA neither at
baseline and 2-years follow-up. Of the 129 participants withmissing
data at 2 years follow-up, eight had PFOA at 5-year follow-up.
A total of 54 patients had TFOA at 5-year follow-up: 29 already
had TFOA at 2-years follow-up, 17 did not have signs of OA at
baseline and 2-years follow-up and seven patients had missing data
at 2-years follow-up. A total of 102 patients had COA at 5-year
follow-up: 56 (54.9%) already had COA at 2-years follow-up and
PFOA at baseline, while 6 (5.9%) had PFOA at baseline and 2-year
follow-up and progressed to COA. Five out of the 102 patients
developed COA while they were diagnosed with PFOA at 2-years
follow-up, and eight progressed from TFOA at 2-year follow-up to
COA. Seven patients with COA at 5-year follow-up did not have signs
of OA at baseline and 2-year follow-up and three patients with COA
at 5 years follow-up had missing data at 2-years follow-up (Fig. 1).
Multivariate regression analysis for different types of OA at 2-year
follow-up
No significant differences in clinical signs and symptoms were
found between participants with radiographic PFOA or TFOA
Table II
Patient characteristics and symptoms at baseline and at 2-year follow-up per group: variables are n [%] unless stated otherwise


















Age (years), mean [SD] 57.8 [4.82] 55.5 [5.16] 56.4 [5.18] 55.9 [5.18] <0.01
Sex (female) 89 [76.7%] 473 [80.2%] 110 [79.1%] 672 [79.5%] 0.70
BMI (kg/m2), mean [SD] 28.1 [4.55] 26.1 [4.00] 26.0 [4.21] 26.3 [4.15] <0.01
Bilateral complaints (yes) 61 [52.6%] 324 [54.9%] 76 [54.7%] 461 [54.6%] 0.33
Hip and knee pain at baseline (yes) 42 [36.2%] 324 [54.9%] 65 [46.8%] 431 [51.0%] 0.06
Pain when walking on flat surface (yes) 21 [18.1%] 96 [16.3%] 26 [18.7] 143 [16.9%] 0.72
Pain when going up or down stairs (yes) 61 [52.6%] 258 [43.7%] 68 [48.9]z 387 [45.8%] 0.13
Baseline WOMAC function (0e68), mean [SD] 25.9 [17.2] 22.7 [16.9] 27.4 [18.4] 23.9 [17.3] <0.01
Crepitus (yes) 72 [62.1%] 271 [45.9%]y 55 [39.6%]y 398 [47.1%] <0.01
Bony enlargement (yes) 12 [10.3%] 21 [3.6%]y 4 [2.9%]y 37 [4.4%] <0.01
Patellofemoral grinding test (pos) 46 [39.7%]x 159 [26.9%]y,x 32 [23.0%]y,k 237 [28.0%]x <0.01
Knee flexion ROM (degrees), mean [SD] 130.8 [10.6]z 135.1 [8.88]z 133.4 [12.5]z 134.2 [9.92] <0.01
Knee extension ROM (degrees), mean [SD] 2.63 [2.68]z 2.73 [2.77]z 2.28 [2.46]z 2.64 [2.74] 0.24
Knee effusion (yes) 15 [12.9] 43 [7.3] 5 [3.6%]y 63 [7.5] 0.02
Morning stiffness knee < 30 min (yes) 85 [73.3%] 356 [60.3%]y 92 [66.2%] 533 [63.1%] 0.02
Joint line tenderness (yes) 49 [42.2%] 273 [46.3%] 53 [38.1%] 375 [44.4%] 0.22
K&L score 1 (yes) 89 [76.7%] 243 [41.2%]y 5 [3.6%]y,k 343 [46.7%]k <0.01
Characteristics at 2-year follow-up n ¼ 39 n ¼ 77 n ¼ 83 n ¼ 517 n ¼ 129 n ¼ 845
Age (years), mean [SD] 58.5 [5.54] 59.3 [5.39] 59.7 [4.16] 57.5 [5.21]y 56.3 [5.15] 58.1 [5.17] <0.01
Sex (female) 33 [84.6] 58 [75.3] 68 [81.9] 407 [78.7] 106 [82.2%] 672 [79.5] 0.65
BMI (kg/m2), mean [SD] 26.7 [3.81] 26.4 [4.27] 28.4 [4.67]y 25.7 [3.75] 26.3 [3.95] 26.2 [4.06] <0.01
Bilateral complaints (yes) 17 [43.6] 38 [49.4] 51 [61.4] 217 [42.0] 70 [54.3%] 367 [43.4] 0.03
Pain when walking on flat surface (yes) 18 [46.2] 12 [15.6] 21 [25.3] 75 [14.5] 29 [22.5%]z 143 [16.9] 0.07
Pain when going up or down stairs (yes) 6 [15.4] 37 [48.1] 56 [67.5] 214 [21.4] 62 [48.1%]z 387 [45.8] 0.02
WOMAC function (0e68), mean [SD] 19.5 [16.2] 24.9 [20.1] 27.8 [17.7] 21.2 [17.1] 26.9 [18.8] 22.9 [17.8] <0.01
Crepitus (yes) 18 [46.2] 40 [51.9] 49 [59.0] 201 [38.9] 54 [41.9%] 339 [40.1] 0.03
Bony enlargement (yes) 1 [2.6] 8 [10.4] 6 [7.2] 24 [4.6] 5 [3.9%] 43 [5.1] 0.23
Patellofemoral grinding test (pos) 4 [10.3]k 17 [22.1]x 20 [24.1]x 88 [17.0]x 30 [23.3%]k 142 [16.8]k 0.28
Knee flexion ROM (degrees), mean [SD] 134.6 [8.02]z 136.9 [9.07]z 130.0 [10.4]y 136.1 [8.50] 133.4 [13.2]z 135.3 [9.09]z <0.01
Knee extension ROM (degrees), mean [SD] 2.19 [2.23]z 2.52 [3.27]z 2.84 [2.99] 2.69 [2.63] 2.55 [2.78]z 2.64 [2.74]z <0.01
Knee effusion (yes) 4 [10.3] 2 [2.6] 11 [13.3]y 27 [5.2] 5 [3.9%] 50 [5.9] 0.03
Morning stiffness knee < 30 min (yes) 22 [56.4] 49 [63.3] 56 [67.5] 288 [55.7] 83 [64.3%] 464 [54.9] 0.23
Joint line tenderness (yes) 6 [15.4] 15 [19.5] 28 [33.7] 164 [31.7] 53 [41.1%] 242 [28.6] 0.04
n: number, m: meter, kg: kilogram, pos: positive, OR: odds ratio.
Bold indicates: P-value <0.01.
*P-value between groups using ANOVA analyses.
y Posthoc Bonferroni analysis: significant different compared to PFOA.
z Data missing in >5% to 10% cases.
x Data missing in >10% to 20% cases.
k Data missing in >20% cases.
Fig. 1. The blocks with the different shades of grey indicate the number of patients with OA. At follow-up the blocks in the different shades of grey below the different blocks at the
previous time point indicate the number of patients that remained the same type of OA or developed another type of OA. In the upper graphic one block is indicating 10 subjects,
whereas in the enlargement one block is indicating one subject.
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were more likely to have a lower knee flexion range of motion (OR
0.94, 95% CI 0.89e0.98). Participants without radiographic knee OA
had better knee function (lower WOMAC scores) compared with
those with isolated PFOA (OR 0.97, 95% CI 0.95e0.99) and reportedmore joint line tenderness comparedwith thosewith isolated PFOA
(OR 3.13, 95% CI 1.47e6.69). Participants without radiographic OA
tended to be younger, were less likely to have palpable bony
enlargement and were less likely to have crepitus during knee
flexion compared to those with isolated PFOA (Table III).
Table III
Multivariate regression analysis for different types of OA at 2-year follow-up
TFOA vs PFOA COA vs PFOA NOA vs PFOA
n ¼ 39 vs n ¼ 77 n ¼ 83 vs n ¼ 77 n ¼ 517 vs n ¼ 77
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Sex (female) 2.69 0.71e10.1 0.15 1.01 0.38e2.69 0.99 1.03 0.52e2.03 0.94
BMI (m/kg2) 0.95 0.84e1.08 0.45 1.07 0.98e1.18 0.14 0.95 0.88e1.02 0.17
Age (years) 0.98 0.89e1.08 0.70 1.02 0.93e1.12 0.68 0.93 0.88e0.99 0.02
Pain when walking on flat surface (yes) 0.42 0.07e2.58 0.35 1.91 0.53e6.83 0.32 1.13 0.44e2.90 0.81
Pain when going up or down stairs (yes) 0.58 0.14e2.52 0.47 1.33 0.46e3.85 0.60 1.20 0.55e2.59 0.65
WOMAC function (0e68) 1.01 0.97e1.05 0.70 0.97 0.94e1.00 0.08 0.97 0.95e0.99 <0.01
Crepitus (yes) 0.47 0.16e1.38 0.17 1.04 0.45e2.41 0.92 0.54 0.30e0.97 0.04
Bony enlargement (yes) 0.18 0.02e1.78 0.14 0.25 0.05e1.12 0.07 0.36 0.13e0.96 0.04
Knee extension ROM (degrees) 0.96 0.74e1.25 0.77 0.85 0.68e1.07 0.17 1.09 0.96e1.25 0.20
Knee flexion ROM (degrees) 0.94 0.88e1.00 0.04 0.94 0.89e0.98 <0.01 0.98 0.94e1.01 0.16
Joint line tenderness (yes) 0.56 0.14e2.33 0.43 2.18 0.83e5.73 0.11 3.13 1.47e6.69 <0.01
Patellofemoral grinding test (pos) 0.62 0.15e2.48 0.50 1.23 0.46e3.30 0.69 0.85 0.42e1.73 0.65
R2 0.19 0.24 0.15
Dependent variable PFOA.
Abbreviations: m: meter, kg: kilogram, pos: positive, OR: odds ratio, NOA: no radiographic osteoarthritis, R2: coefficient of determination.
Bold indicates: P-value <0.01.
Italics indicates: P-value >0.01 and <0.05.
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The results of this study suggest that combined OAmay start in
the PF joint and then progresses to COA. At baseline, 16.4% of our
participants with symptoms of early knee OA were diagnosed
with radiographic isolated PFOA and none with isolated TFOA and
at the 2-year follow-up, half of the participants with PFOA at
baseline had developed COA, and at 5-year follow-up two thirds of
the participants with isolated PFOA at baseline had developed
COA. The incidence of COA and TFOA in patients that presented
with symptoms of knee OA was low, i.e., 3.1e6.6%, respectively at
the 2-year follow-up and 1.4e4.5%, respectively, at the 5-year
follow-up.
Compared to the CAS(K) studies20,25,37,38, in the present study
the prevalence of PFOA at baseline was lower (23.9% vs 16.4%,
respectively) and this difference remained at follow-up (28.8% at 3
years follow-up in the CAS(K) study vs 4.6% at 2 years follow-up in
the present study)20. These differences in prevalence and incidence
are probably explained by the different populations in the studies.
The CAS(K) studies20,25 comprised older patients with a higher BMI
compared to our CHECK population. However, it was notable that,
compared to Thorstensson et al.27 who also included middle-aged
participants (age range 35e54 years) with chronic knee com-
plaints (>3 months), we found a lower prevalence of TFOA at
baseline (47% vs 0%, respectively). Therefore, the differences in
prevalence and incidence might not only be due to different pop-
ulations but might also be attributed to the use of inconsistent
definitions for knee OA39. The inconsistency in definitions of
radiological OA in studies evaluating different OA types may have
led to misclassification into the different OA groups40. This em-
phasises the need for consensus on the radiographic classification
system used for OA39.
It is noteworthy that in the present study, none of the partici-
pants had TFOA at baseline. This can probably be explained by our
study population as most participants had not visit a GP or physi-
cian for their knee symptoms yet. However, the absence of TFOA in
the present study might also be explained by detectability of the
abnormalities of the different radiographs. It could be possible that
on skyline radiographs osteophytes are earlier detectable than
osteophytes on the PA radiograph, so that PFOA is earlier detectable
with radiographs compared to TFOA. This may be strengthened by
the findings of Stefanik et al. (2016) in which isolated PFOA was
already seen at baseline, though in a relatively older population21.Though similar to our study, knees that developed OA in both the
PFJ and TFJ started with damage isolated to the PFJ. It therefore
seems important to get more insight in the patient populationwho
develop combined knee OA and develop preventative and thera-
peutic strategies targeting the PFJ.
In the literature, three main signs of OA that were determined
on physical examination (i.e., crepitus, restricted movement, and
bony enlargement) were found to be associated with the devel-
opment of radiographic OA2. These positive physical examination
findings increase the risk of radiographic OA2. However, the present
results indicate the difficulty of discriminating between the
different types of OA using the measures from clinical history and
physical examination. However, the results do indicate that par-
ticipants with COA had a lower knee flexion ROM compared to
those with isolated PFOA, and a trend was seen in participants with
TFOA; i.e., they also had a lower knee flexion ROM compared to
those with isolated PFOA. Consistent results were reported in
another cross-sectional study on clinical features of symptomatic
OA, showing that lower knee flexion ROM was an indicator for
radiographic COA and not for radiographic PFOA25. Furthermore,
this latter study also reported that lower knee flexion ROM was an
indicator for TFOA25. It is proposed that knee flexion ROM is an
important clinical finding in (especially) participants with severe
radiological signs of OA41. In the present cohort, the majority of the
participants with knee symptoms had PFOA at baseline and this
was already associated with reduced knee flexion ROM. Therefore,
reduced knee flexion ROM seems to be an early sign of knee OA.
However, it is questionable whether the ROM can distinguish be-
tween those with isolated PFOA, and those with TFOA and COA, in
middle aged persons with knee symptoms.
It is noteworthy that participants without radiographic signs of
OA were more likely to have joint line tenderness compared to
thosewith PFOA. It could be hypothesised that joint line tenderness
might be associated with other intra-articular pathologies (e.g.,
meniscus) that are not seen on radiographs. This hypothesis is
strengthened by the fact that, when the K&L grade 1 variable was
added to the multivariate regression model to test differences in
phenotype between patients without radiographic signs of OA and
those with PFOA, the significant association between joint line
tenderness remained (data not shown).
The strength of the present study is that wewere able to analyse
a large cohort of relatively young subjects with early knee symp-
toms so that the natural course of OA could be evaluated. However,
N.E. Lankhorst et al. / Osteoarthritis and Cartilage 25 (2017) 647e653652the study also has some limitations. In this relatively young cohort
of participants with symptoms of knee OA, X-rays may not be
sufficiently sensitive to detect early OA features and changes that
are detectable onMRI42. On the other hand, these participants were
followed over 5 years, a period in which radiographic signs are
expected to progress43.
Due to the small number of participants with TFOA we were
unable to test for differences in phenotype based on baseline
characteristics; therefore, we performed a cross-sectional analysis
with the 2-year follow-up data. Furthermore, a limited number of
variables were included in the regression analysis. Additional
variables measured in the CHECK study (including clinical hand
OA, profession, and physical activity) and reported to be risk fac-
tors for knee OA, might also differ between patients with PFOA and
TFOA43. The explained variance in the regression model was low,
indicating that other factors not included in the present study (e.g.,
quadriceps strength, malalignment) might be able to differentiate
between the different types of OA19,25,43. These biomechanical
variables could be potential targets for specific treatments for
PFOA44.Implications for future research
None of the participants in the present study had TFOA at
baseline and 116 had PFOA. This suggests but does not prove that
combined OA is more likely to start in the PF-joint. Furthermore,
two-thirds of the participants that had PFOA at baseline progressed
to COA at the 5-year follow-up (assuming that the status of the
seven participants with COA at 2-year follow-up butmissing data at
5-year follow-up did not change), whereas only 20% of the partic-
ipants that had TFOA at the 2-year follow-up progressed to COA at
the 5-year follow-up. This indicates that, in those who have their
first signs of radiographic OA in the PF joint, they are more likely to
progress to COA compared to thosewith isolated radiographic signs
of OA in the TF joint. This is in agreement with earlier studies20,38.
Additionally, this was recently strengthened by Stefanik et al.
(2016) showing that patients with isolated PFOA on MRI at baseline
were 2.1 times more likely to develop combined OA compared to
patients with isolated TFOA at baseline21. However, a longer follow-
up period is needed to determine whether all participants with
PFOA at baseline will develop COA, or whether there are more
subgroups within the PFOA population (e.g., stable PFOA, progres-
sion to COA, and progressive PFOA).Conclusion
The results of this study suggest that combined OA seems to
start in the PF joint and then progress to COA. Differences in TFOA
and PFOA phenotypes could not be determined with respect to
signs and symptoms. A longer follow-up is necessary to determine
whether all participants with PFOA will eventually develop COA.Contributors
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